id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S15197 R62332 |
Cohen (Lamotrigine) (Mixed indications), 2023 | Hypospadias | 1st trimester | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Partial overlapping | 1.01 [0.66;1.55] | -/8,339 -/4,866,362 | - | 8,339 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10035 R36163 |
Blotière (Lamotrigine) (Mixed indications), 2019 | Hypospadias | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes | 1.20 [0.60;2.60] | 7/2,997 3,371/1,875,733 | 3,378 | 2,997 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8964 R30359 |
Veiby (Lamotrigine) (Controls unexposed, disease free) (Mixed indications), 2014 | Hypospadias | throughout pregnancy | population based cohort retrospective | unexposed, disease free | Adjustment: No Partial overlapping | 2.41 [0.90;6.44] C | 4/833 1,543/771,412 | 1,547 | 833 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8908 R30105 |
Källén (Lamotrigine) (Indications NOS), 2013 | Hypospadias | early pregnancy | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Partial overlapping | 0.87 [0.18;2.04] | 3/1,084 4,552/1,575,847 | 4,555 | 1,084 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 4 studies | 1.14 [0.82;1.59] | 9,480 | 13,253 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Lamotrigine) (Mixed indications; 2: Lamotrigine) (Mixed indications; 3: Lamotrigine) (Controls unexposed, disease free) (Mixed indications; 4: Lamotrigine) (Indications NOS;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded